1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
The Greater Cannabis Company, Inc.

The Greater Cannabis Company, Inc.

GCAN
The Greater Cannabis Company, Inc.US flagOther OTC
0.15
USD
+0.00
- -
137,016.00Market Cap
The Greater Cannabis Company, Inc.
GCAN
(Other OTC)

Recent

price

0.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
-0.03
-0.05
-0.01
- -
- -
- -
-0.33
-0.4
- -
Basic EPS, GAAP
- -
- -
- -
-0.01
- -
- -
- -
- -
-0.2
-0.07
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
-0.03
-0.07
-0.02
-0.01
-0.01
- -
-7.19
-4.41
-0.01
Book Value per Share
- -
- -
-0.02
-0.04
- -
- -
- -
- -
-1.58
-0.91
- -
Tangible Book Value per Share
30
30
30
35
145
490
588
755
1
1
430
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
-200.18
-6,398.51
-612.89
-2,716.91
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
-1
-2
-1
-1
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-879.76
-23,154.42
-1,979.79
-4,768.22
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-1
-2
- -
- -
-1
-1
-1
-1
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
-1
-2
- -
- -
-1
-1
-1
-1
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
11.26
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
1
Market Capitalization
- -
32
107

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
1
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
24.1%
-11.74%
Free Cash Flow
- -
-24.49%
-45.06%
Net Income, GAAP
- -
-8.87%
85.22%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
-0.09
- -
-0.33
2025
-0.17
- -
-0.04
- -
-0.4
2026
-0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Hikal Limited (HIKAL.BO)
Amphastar Pharmaceuticals, Inc. (AMPH)
CannLabs, Inc. (CANL)
Bloomios, Inc. (BLMS)
RLS Global AB (publ) (RLS.ST)
4Front Ventures Corp. (FFNT.CN)
Business
The Greater Cannabis Company, Inc. (GCAN) develops and commercializes cannabinoid therapeutics for neuropsychiatric disorders. The company offers an oral transmucosal patch platform that delivers active cannabinoids absorbed through the buccal mucosa; it maintains a license agreement with Shaare Zedek Scientific Ltd. targeting autism spectrum disorders, schizophrenia, Parkinson’s disease, Alzheimer’s disease, and related conditions; and pursues additional research and development of pharma-grade neuroprotective therapeutics, including a recently approved Israeli Ministry of Health study evaluating safety and efficacy for autism-related symptoms. Founded in 2014 and headquartered at 2833 Smith Avenue in Baltimore, Maryland, the biopharmaceutical firm operates primarily in the United States with one employee and focuses on cannabis-related investment opportunities through equity investments, joint ventures, licensing, and acquisitions. In December 2025, the company secures relisting on the OTCQB Venture Market tier to enhance transparency and broker access.

Company News

APIChat

  • globenewswire.com

    R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease

  • globenewswire.com

    GCANRx Announces Relisting To OTCQB Market Tier

  • globenewswire.com

    GCANRx Announces Uplisting to New Market Tier

  • globenewswire.com

    GCAN to Explore Strategic Alternatives in Artificial Intelligence and Quantum Computing

  • https://www.defenseworld.net

    Meridian Wealth Management LLC Makes New Investment in InterContinental Hotels Group PLC (NYSE:IHG)

  • https://www.defenseworld.net

    Dimensional Fund Advisors LP Purchases 140,347 Shares of Tapestry, Inc. (NYSE:TPR)

  • https://www.defenseworld.net

    Koninklijke Philips (NYSE:PHG) Shares Sold by National Bank of Canada FI

  • globenewswire.com

    GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy

  • globenewswire.com

    GCANRx Featured in American Journal of Endocannabinoid Medicine

  • globenewswire.com

    GCANRx Signs Licensing Agreement with Shaare Zedek Scientific for Innovative Neuropsychiatric Cannabinoid Therapy

  • globenewswire.com

    GCANRx Announces Collaboration with Renowned Cannabis Research Lab